Skip to main content

Advertisement

Figure 2 | BMC Neurology

Figure 2

From: Identification of the soluble form of tyrosine kinase receptor Axl as a potential biomarker for intracranial aneurysm rupture

Figure 2

Confirmation of the changes of CSF sAxl levels in both discovery and validation cohorts using ELISA. (A) sAxl concentration in individual CSF samples from the discovery cohort (n = 10 per group). (B) sAxl concentration in individual CSF samples from the validation cohort (n = 20 per group). *p <0.05 and **p <0.01 (Newman-Keuls test). Error bars represent the 95% confidence interval of the mean.

Back to article page